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Ulster says 'NO'; explosion, resistance and tolerance
Nitric oxide and the actions of organic nitrates
G D Johnston
Those who have started to read this review
expecting adiscussionofthepolitical situationin
Northern Ireland will either be relieved or
disappointed. Thetitlereferstothediscovery and
actions of nitric oxide and the role played by
investigators inNorthernIreland, itsrelationship
to the explosive nitroglycerine and the concepts
of nitrate resistance and tolerance in
cardiovascular medicine.
In 1867ThomasBrunton, anewlyqualifiedhouse
surgeon at the Edinburgh Royal Infirmary
pioneered the clinical use of the
sphygmomanometer by employing it to monitor
the increase in blood pressure associated with
episodes of angina pectoris. Brunton speculated
thatamylnitrite, adrugwhichhehadobservedto
lowerbloodpressureinanimals, mightbeusedto
relieve angina pectoris. He obtained a sample of
amyl nitrite and poured it on to a cloth for his
patient to inhale. Within a minute the pain
disappeared andthepatientremainedfreeofpain
for several hours.' Along with other nitrates and
nitrites Brunton investigated the compound
nitroglycerinewhichhadbecomewidelyavailable
followingAlfredNobel'sdiscoveryofitsproperty
asanexplosive. Laterthefollowingyear,William
Murrell, a registrar at the Westminster Hospital
decided to resolve the conflicting reports in the
literature as to whether nitroglycerine caused
severe headache or not. The French chemist,
Ascagne Sobrero, who had first synthesised the
compound, reported in 1847 that he experienced
an intense headache after tasting a small drop
placed on his finger. Others had similar
experiences including Arthur Field, a Brighton
dentist who claimed in the Medical Times and
Gazette that if placed on the tongue it could
alleviate toothache and neuralgia. He contended
that it would be a highly effective remedy for
these conditions if it were not for the severe
accompanying headache. In contrast, others
reported no effects whatsoever after swallowing
largeamountsofnitroglycerine.Murrellsuspected
that the differences were largely due to variation
in the susceptibility ofdifferent individuals, and
decided to conduct an experiment in healthy
volunteers. In the course ofone ofhis outpatient
clinics he licked the moist cork of the bottle
containing nitroglycerine solution and within a
few seconds began to experience a throbbing
headache and a pounding in the chest. After five
minutes he had recovered sufficiently to resume
his clinic but the headache persisted for most of
the afternoon. With further experimentation,
Murrell determined three important pharma-
cological properties ofnitroglycerine; the effect
lasted longerthan amyl nitrite, the headache was
usually related to overdosage and larger doses
were required if the drug was swallowed than if
it was allowed to dissolve slowly in the mouth.
Murrell treated his first patients with
nitroglycerine in 1878 and the following year
published his report in the Lancet.2 As a result,
nitroglycerine was introduced into clinical
practice for the treatment of angina pectoris.
British doctors took steps to avoid any
unnecessary alarm that might result if patients
discovered that they were receiving the same
explosive that was in dynamite and renamed the
compound glyceryl trinitrate. No such niceties
were adopted by their American colleagues, and
in the United States the drug is still known as
nitroglycerin. Thehighlipidsolubilityofglyceryl
trinitrate facilitates good absorption across the
buccalmucosaandthepoorerresponse seenafter
oral absorption relates to first pass metabolism
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by the liver. The headache is due to the well-
described vasodilator effects of nitrates on the
extra-cranial blood vessels.
Despite widespread use of organic nitrates for
over a century, the method by which they dilated
veins and arteries was unknown. A new chapter
in cardiovascular physiology and pharmacology
opened in the early nineteen eighties with the
discovery of a hitherto unknown vasodilator
substance produced by the vascular endothelium
EDRF (endothelium derived relaxing factor).3
This compound is one of the most active
endogenous vasodilators and is involved in the
modulation of blood vessel tone. It took almost
eight years of intense research to establish that
thisvasodilatorcompoundwasoneofthesmallest
molecules known, NO (nitric oxide).4 Organic
nitratesentervascularsmoothmusclecellswhere
they are reducedby sulphydryl groups to liberate
nitric oxide. This in turn activates the enzyme
soluble guanylate cyclase which converts
guanosine triphosphate(GTP)tocyclicguanosine
monophosphate (cGMP) resulting in reduced
intracellular calcium concentrations and smooth
muscle relaxation (Figure 1). Sodium
nitroprusside is an inorganic nitrate which forms
nitric oxide directly without the need for
biotransformation. Itis ausefultoolforassessing
vascular smooth muscle responsiveness to nitric
oxide, and distinguishing between impaired
dilatorresponseswhichareduetoanabnormality
in the vascular smooth muscle, and those due to
an endothelial defect. Recent observations have
suggested that resistance to the action ofnitrates
occursinasignificantpercentageofthepopulation
probably due to deficiency of intracellular
sulphydryl donors, and this is more commonly
Fig 1. Proposed action of nitrodilators and nitric oxide in smooth muscle cells
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seen in diabetes mellitus5 6 and heart failure.7'8
Continuous administration of organic nitrates
can also lead to vascular tolerance through a
similar mechanism. Repeated doses probably
resultinfewerS-nitrosothiols, leadingtoreduced
activation of guanylate cyclase and a lower
concentration of cyclic GMP with a resulting
decrease in vascular relaxation.9
THE PHYSIOLOGY AND PHARMACOLOGY OF
NITRIC OXIDE
Endothelialcellssecretenitricoxidewhichrelaxes
vascular smooth muscle.10 Under physiological
conditions NOis constantlyreleasedandensures
patency of the blood vessel. In the endothelial
cells, NO is synthesised from the amino acid L-
arginine by NO-synthase.1' This enzyme is
continuously activeensuringtheconstantrelease
ofNO. Disturbances in endothelial cell function
decrease the production of NO and thus reduce
vasodilation.5'12 In addition to NO, endothelial
cells alsoreleaseprostaglandins withvasodilator
activity such as prostacyclin. This endoperoxide
induces vasodilation and inhibits platelet
aggregation.12Damaged orexcessively activated
endothelial cells can also secrete vasconstricting
factors of which the recently discovered
endothelin-I is the best known.13 Although
thromboxane, a powerful vasoconstrictor, is
producedbyactivatedplatelets, itis alsoreleased
by damaged endothelial cells14 (Figure 2).
Fig2. Effectsofplateletaggregation ontheendot1helium andvascularsmoothmuscle
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Threenitricoxidesyntheseshavebeendescribed;
an endothelial isoform (eNOS), a neuronal
isoform (nNOS) in nitrergic nerves and a
macrophage or inducible isoform (iNOS). The
genesencodingthethreeisoformsofNOsynthase
have been located on human chromosome 7
(eNOS), 12 (nNOS) and 17 (iNOS). 15"16'17Thetwo
predominant isoforms of NOS are eNOS and
nNOS. Theinducible formoftheenzyme is iNOS
found in endothelial, smooth muscle and several
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other cells. It is involved in host defence
mechanisms and immunological reactions. The
constitutive form ofNO synthase is expressed in
endothelial cells andis involvedintheregulation
of vascular tone, structure and haemostasis. A
widerangeoffactorshavebeenfoundtostimulate
the constitutive form of NO synthase including
mechanical factors (shear stress and pulsatile
pressure),plateletproducts(bradykinin, serotonin
and histamine) and neurohormonal mediators
(angiotensinII,acetylcholineandnoradrenaline).
Arteries produce more nitric oxide than veins,
although veins respond better to organic
nitrodilators. The biological half life is
approximately thirty seconds and it is rapidly
inactivated by haemoglobin, methylene blue and
the superoxide anion. The development of
competitive inhibitors of NO synthase, the L-
arginine analogues NG monomethyl-L-arginine
(L-NMMA)andNGnitro-L-argininemethylester
(L-NAME) has provided an invaluable tool for
investigation of the role of NO in biological
processes. Inadditiontomovementofnitricoxide
fromtheendotheliumtovascularsmoothmuscle,
nitric oxide is also released into the lumen of
blood vessels. Here it acts synergistically with
prostacyclin to inhibit platelet aggregation,
smooth muscle growth and cell proliferation."8
Thereis increasing evidence thatnitric oxide has
important physiological effects throughout the
bodyandproductionisnotconfinedtothevascular
endothelium. Nitric oxide is present in lung
epithelium and other pulmonary cells and has
beensuggestedasthemediatorofnervedependent
bronchodilatation.19Reducednitricoxiderelease
mayalsobethemechanismunderlyingpulmonary
vasoconstriction which occurs secondary to
hypoxia20andinhalednitricoxidehasbeenshown
to reduce pulmonary vasoconstriction and the
elevatedpulmonarypressureoccurringinchronic
hypoxia. Thereisrecentevidencethatnitricoxide
also has an important role in the central nervous
systeminprotectingneurones fromdegeneration
and mediating neuronal activity and nutritive
bloodflow. Inhighconcentrationshowever, there
is experimental evidence to suggest that nitric
oxide may cause neuronal damage.21' 22 Other
functions of nitric oxide include control of
gastrointestinal sphinctertone andmotility,23 the
release of insulin in diabetic patients,24 penile
erection,25 regulation of lymphocyte function26
and producing vasodilation and tissue leakage in
the inflammatory response.27
ENDOTHELIAL DYSFUNCTION AS A MARKER
FOR VASCULAR DISEASE
The discovery of Furchgott and Zawadzki in
1980 ofthe obligatory role ofthe endothelium in
producing vascular smooth muscle relaxation in
responsetoacetylcholine3hasprovidedavaluable
method for assessing endothelial function. This
methodhasbeenwidelyusedtoassessendothelial
function in vivo in animals and humans. Most in
vitrostudiesofendothelium-dependentrelaxation
involve mounting an isolated artery in an organ
bath. Thelengthofthearteryisfixedandchanges
in isometric tension recorded. The artery is
preconstricted with noradrenaline or
phenylephrine and the relaxation in response to
an endothelium-dependent vasodilator such as
acetylcholine or serotonin recorded. In order to
confirm that impaired vasodilatation is due to
endothelial dysfunction, relaxation in response
to an endothelium-independent vasodilator,
usuallysodiumnitroprussideorglyceryltrinitrate
is also determined. This helps to exclude non-
specificimpairmentofsmoothmusclerelaxation.
The method has been used to demonstrate
impaired endothelial function in animals with
diabetes,28 hypercholesterolaemia,29 hyper-
tension30 and vessels with evidence of
atherosclerosis.3' A small number of studies
investigatingendothelialfunctioninsmallerblood
vessels have been carried out in diabetic animals
examining pial,2 retinal33 or mesenteric34
arterioles. Saenz de Tejada et al 1989
demonstrated that isolated penile corpora
cavernosum tissue from diabetic and control
subjects taken at the time of penile prosthesis
implantation had impaired responses to
acetylcholine.35 The technique of venous
occlusionplethysmographyhasbeenwidelyused
to assess endothelial function in human subjects.
Thismethodinvolvesthemeasurementofforearm
bloodflowinresponsetoendothelium-dependent
andindependentvasodilatorsinfusedlocallyinto
the brachial artery.5 It is the method which we in
the Department of Therapeutics and
Pharmacologyhaveusedmostfrequentlytoassess
endothelialfunctioninavarietyofdiseasedstates.
Alternatively other vascular beds can be used,
particularly those in the coronary circulation.36
EFFECT OF DISEASE ON ENDOTHELIAL
FUNCTION
Thevasodilatory functionofendothelial cellshas
an essentialrole inmaintaining thephysiological
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Fig 3. Factors associated with endothelial activation and damage
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activity of blood vessels. Disturbances in
endothelial cell function decrease the release of
nitric oxide and reduce vasodilation (Figure 3).
Damaged or excessively activated endothelial
cells secrete endothelin-1 and produce a variety
of adhesion molecules and chemotactic
substances. As aresult, leucocytes migrate to the
endothelial wall.37
Near the wall they slow down and adhere to
endothelial cells. This process of cell adhesion
hasbeendescribed overalongperiodoftime and
some of the underlying molecular mechanisms
have recently been identified.
Endothelial cells induce adhesion by expressing
specific surface adhesion molecules which
interactwithligands onleucocytes andplatelets38
(Figure 4). Three groups of adhesion molecules
haverecentlybeenidentified: afamilyofselectins
including E selectin and L selectin, a group of
integrins such as LFA-1 (leucocyte function-
associated antigen) and a supergene family of
immunoglobulins such as ICAM-1 (intracellular
adhesion molecule) and VCAM (vascular cell
adhesion molecule). These adhesion molecules
areexpressedafterstimulationofendothlialcells
by specific factors such as tissue necrosis factor
(TNF-a). This expression is increased on
endothelial cells chronically damaged by risk
factors for atherosclerosis such as smoking,
hypertension and hypercholesterolaemia. In
addition, high blood glucose concentrations and
increased LDL cholesterol induce increased
expression ofligands such as integrins which are
the binding proteins for adhesion molecules.
Binding ofblood cells to the endothelium affects
the pathogenesis of atherosclerosis in several
ways.39 Increased binding of leucocytes and
platelets leads to changes in the laminar blood
flow and to the generation ofturbulence which in
Fig 4. Factors involved in the regulation ofendothelial cell adhesion
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turn increases platelet aggregability and risk of
thrombosis. The binding of leucocytes to the
endothelium also affects the production and
release of reactive oxygen species from these
cells.40 In hyperglycaemic conditions binding of
monocytes to glycosylated proteins can also
occur.41
In diabetes and hyperlipidaemia disturbed
permeability ofthe endothelial layerresults in an
increased movement of substances from the
circulation into the vessel wall.42 Insulin can
migrateacrossthecelllayerandstimulate smooth
muscle cell proliferation and the mitogenic and
migratoryactivityofotherfactors suchasPDGF43
(platelet derived growth factor). In addition,
endothelial cell dysfunction can lead to
accelerated intravascular blood coagulation by
reducing nitric oxide and prostacyclin formation
and decreasing fibrinolytic activity44 (Figure 2).
(1) Diabetes and endothelial function
Therelationshipbetweendiabetesanditsvascular
complications is complex but it seems likely that
damagetothevascularendotheliumplays amajor
role. Exposure of plasma and cell membrane
proteins to hyperglycaemic conditions for
prolonged periods results in the attachment of
glucose molecules to proteins, a process known
as non-enzymic glycosylation. Further slow
reactions result in the formation of advanced
glycosylationend-products(AGEs)45 whichhave
been shown to inactivate nitric oxide and impair
endothelium-dependent vasodilation.46 However
these vascularresponses are alsoimpairedduring
shorttermhyperglycaemia suggesting thatthis is
nottheprincipal mechanism.47 In the presence of
hyperglycaemia, thephytolmetabolicpathway is
stimulated resulting in an increased utilisation of
NADPH. Since NADPH is an essential co-factor
for nitric oxide synthase reduced availability
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withinthecellcouldresultinreducednitric oxide
production. Depletion of NADPH could then
result in enhanced oxidative stress and increased
susceptibility to free radical attack. Aldose
reductase inhibitors have proved effective in
restoring endothelial function in experimental
diabetes48 although their impact on the vascular
complications ofdiabeteshasbeendisappointing.
Increasedoxidative stressindiabetesresultsfrom
several different sources. These include phytol
pathway activity, auto-oxidation of glucose and
reduced antioxidant concentrations including
vitamin E and ascorbic acid.49 The resulting
increase in free radical activity in diabetes can
cause cellular damage and inactivation of nitric
oxide. Several studies have demonstrated
improvedendothelialfunctioninresponsetofree
radical scavengers in diabetic animals.50
Near the wall they slow down and adhere to
endothelial cells. This process of cell adhesion
has beendescribed overalong periodoftime and
some of the underlying molecular mechanisms
have recently been identified.
Although the causes of vascular damage in
diabetes are in large part due to hyperlgycaemia,
other metabolic factors probably contribute.
Hyperlipidaemia is associated with endothelial
dysfunction and increased morbidity.5" A large
percentage of patients have lipid abnormalities
including hypertriglyceridaemia, reduced HDL
cholesterol, increased LDL cholesterol and
increased amounts ofoxidised LDL cholesterol.
The role ofoxidised LDL cholesterol in causing
endothelial damage has recently been described
in this department by measuring the cytotoxicity
of LDL cholesterol from diabetic patients in
culturedllendothelial cells.52
Hyperinsulinaemia may also be involved in
producing vascular damage in diabetes and
increasingtheriskofdevelopingatherosclerosis.53
A major hypothesis is that increased insulin
concentrations occurring as a result of insulin
resistance cause sodium retention and increased
sympatheticactivity. Bothfactorstendtoincrease
bloodpressurewhichisassociatedwithincreased
cardiovascular morbidity and endothelial
dysfunction in the absence ofdiabetes.54 Studies
linking hyperinsulinaemia with arterial disease
and hypertension are inconsistent and increased
prevalence ofatherosclerosis andhypertension is
notafeatureofinsulinoma, acondition associated
with extremely elevated insulin levels.55
(2) Hyperlipidaemia and endothelial function
There is now a considerable amount ofevidence
that low density lipoproteins (LDL) impair the
activity ofnitric oxide. This is inpartdue toLDL
itself but most evidence suggests that oxidised
LDL has a more important and lasting effect.56
Endothelial cells, macrophages and vascular
smoothmusclecellscanoxidiseLDLcholesterol.
If this is not removed by antioxidants such as
vitaminEitcanbetakenupbyscavengerreceptors
onthemacrophages whereitaccumulates toform
foam cells and contributes to the development of
atheroma. High levels of circulating LDL
cholesterol have been shown to reduce
endothelium-dependent vasodilatorresponses to
aggregating platelets and prostacyclin release
andcouldpredisposetovasoconstriction,platelet
adhesion and thrombus formation.57
(3) Hypertension and endothelial function
Abnormalities of endothelial function are well
described in hypertension. Endothelium-
dependentdilation is diminished inexperimental
hypertension and in patients with essential
hypertension. Lowering blood pressure in
experimental animals prevents the development
of these abnormalities but abnormal responses
remain to some degree in adequately controlled
hypertensive patients.58
(4) Circulatory shock and endothelial function
If a little nitric oxide is good for cardiovascular
health, large amounts are often dangerous. In
endotoxin shockthere is massive releaseofnitric
oxideleading tovasodilationandhypotension. In
animal models thebloodpressure canberestored
by agents such as L-NMMA whichpreventnitric
oxide production.59 Release of nitric oxide by
endocardial and myocardial cells may also occur
accounting in part for the depressed cardiac
function which occurs in some patients with
endotoxic shock. Increasednitric oxide synthesis
probably also has an important role in
haemorrhagic shock60 and we have recently
demonstrated increased nitric oxide activity in
patients with systemic vasculitis.61
(5) Other diseases associated with abnormal nitric
oxide production
Impairednitricoxideactivityinthelargesystemic
arteries has been demonstrated in congestive
cardiac failure,62'63 in the coronary circulation, in
congestive cardiomyopathy and in vein grafts.
Smokingis alsoassociatedwiththeabnormalities
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ofendothelialandplateletfunctionseeninpatients
withhypercholesterolaemia.S7 Ininfantilepyloric
stenosis a selective depletion of nitric oxide has
been found in the circular pyloric muscle.64
Following theidentification ofanitric oxide-like
factor in brain tissue in 1988 there has been
extensive research on the possible role of nitric
oxide as a neuronal mediator.2' A specific nitric
oxide synthase enzyme has been purified and
cloned and is most abundant in the cerebellum
and olfactory bulbs. 21 In Huntington's disease,
and in cerebral ischaemia it has been suggested
that nitric oxide may protect neurones from
oxidative injury.21 Protection, however, may
depend on the concentration of nitric oxide; at
low levels it appears to have an enhancing,
mediating and protecting role in brain neurones
while at high levels nerve damage seems to be
more likely.
It has also been recently established that nitric
oxide is theprincipal mediatorofpenileerection.
Nitric oxide synthase is localised in pelvic
neurones innervating the corpora cavernosa and
in the neuronal plexuses of the adventitial layer
ofthepenilearteries.25Itseemslikelythaterectile
impotence in diabetic men involves impaired
functionoftheL-arginine-nitric oxidepathway,65
and anecdotal evidence suggests that the local
application of glyceryl trinitrate to the penis of
impotent men causes erection with aheadache in
the sexual partner being the only adverse effect.
Clinical uses of nitric oxide
As discussed previously, drugs which donate
nitric oxide to vascular smooth muscle and
produce vasodilation have been used in clinical
medicineforalmostonehundredandfiftyyears.1
Glyceryl trinitrate preferentially dilates veins, a
principal reason for its clinical value in angina
pectorisandcongestivecardiacfailure.Thereason
forthevenoselectivity couldberelatedtothelow
basal outputofnitric oxide, andconsequently the
guanylate cyclase in venous smooth muscle is
upregulated and responds more readily to
exogenous nitric oxide. By the same reasoning,
reduced nitric oxide synthesis at sites of
endothelial damage or dysfunction in arteries or
arterioles should make these vessels more
sensitive to the actions of nitrodilators. The
antiplatelet effects of nitric oxide provided by
organic nitrates may also have some beneficial
therapeutic effects. Recent studies have focused
on the development of new classes of
nitrovasodilators. S-nitrosoglutathione (GINO)
has recently been shown to have selective
antiplatelet effects.66
New uses for nitric oxide are being explored.
These include the local application of organic
nitrates for the treatment ofimpotence, systemic
administrationforacutestrokeanddelayedlabour
and inhalation of nitric oxide in a variety of
respiratory conditions67 such as respiratory
distresssyndrome,68acutelunginjury,pulmonary
hypertension69 and in diseases associated with
ventilation-perfusion inequality.
Therehavebeenanumberofencouragingreports
on the value ofinhalednitric oxide in pulmonary
hypertension. The condition is frequently
observed in neonatal and in adult respiratory
distress syndromeandfollowingcardiopulmonary
bypass surgery. However, inhaled nitric oxide
remains an experimental form of treatment and
there is no useful information on the benefits of
nitric oxide in any chronic respiratory disease.
Most chronic lung diseases are associated with
structural changes so that the effects of inhaled
nitricoxideareunlikelytoresultinmajorbenefit.
Inhaled nitric oxide is not without its own
problems. Nitric oxide can combine with oxygen
resulting in nitric acid formation and increased
toxic radicals. Methaemoglobinaemia can occur
and at high concentrations it could exert pro-
inflammatory effects.
Other drugs may increase the production of
endogenousnitricoxide. Angiotensinconverting
enzyme inhibitors inhibit the breakdown of
bradykinin whichinturn stimulates thereleaseof
nitric oxide from the endothelium in patients
with coronary artery disease70 and congestive
heartfailure.71 Recentinterest has focused on the
possibility of enhancing nitric oxide production
by providing excess of its substrate L-arginine.
Although arginine is plentiful in the diet and is
not the rate limiting factor for nitric oxide
synthesis, there arereports thatarginine prevents
the onset of atheroma in experimental animals
and improves endothelial function in patients
with hypercholesterolaemia,72 angina73 and in
patients following cardiac transplantation.74 In a
recentstudyinvolvingpatients withheartfailure,
chronic L-arginine supplementation was found
to improve blood flow.75
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Clinical methods and indications for the reduction of
nitric oxide
In some clinical situations it may be valuable to
inhibit the synthesis or activity of nitric oxide.
Inhibition ofnitric oxide synthesis with substrate
analogues such as N0 monomethyl-L-arginine
reverses the local vasodilation associated with
inflammation and the profound hypotension and
cytotoxic effects which occur in endotoxin
shock.59 Selective inhibitors of the inducible
isoform of nitric oxide synthase are being
developed as possible anti-inflammatory drugs.
Suchagentswouldhavethetheoreticaladvantage
that they would inhibit the pathophysiological
production of nitric oxide without impairing
endothelial, neuronal or platelet function. Drugs
in common clinical use may also reduce nitric
oxide synthesis. Corticosteroid drugs inhibit the
induction of nitric oxide synthase but are
ineffective once the enzyme is expressed.
Methotrexate inhibits the synthesis of
tetrahydrobiopterin, an essential cofactor for the
induction and activity ofnitric oxide synthase.76
The relationship between this and the drug's
clinical effect is unknown but the findings raise
the possibility ofdeveloping more specific anti-
inflammatoryorimmunosuppressivedrugsbased
onalterationoftheinduciblenitricoxidepathway.
Nitrate tolerance
Although nitric oxide is the active component of
drugscollectivelyknownasthenitrovasodilators
some are able to release nitric oxide directly
while others require metabolic conversion by
musclecells. Sodiumnitroprussidespontaneously
releases nitric oxide from its complex.77Organic
nitrates such as glyceryl trinitrate, isosorbide
dinitrate and isosorbide mononitrate require the
presence of sulphydryl (SH) groups within the
cellstoreleaseandgeneratenitricoxide78 (Figure
1). With continuous administration of organic
nitrates tolerance to their effects in angina and
heart failure has been described especially ifthe
transdermal route is employed.79'80
Tolerance to the vascular effects of organic
nitrateshaslongbeenrecognisedinthemunitions
industry.81 The headaches, flushing and
lightheadedness experienced during early
exposurebecamelessintenseordisappearedwhen
workers hadbeen exposed for several days. Such
tolerance was shortlived and when workers were
awayfromthefactoryforshortperiods symptoms
recurred on re-exposure. In addition, Lang and
colleagues 1972describedchestpaininmunition
workers during periods away from work which
were thought to be due to coronary
vasoconstriction.82 Current concepts of nitrate
tolerance have focused on impaired intracellular
metabolic conversion of nitrate to nitric oxide.
When tolerance develops there appears to be a
decreasedabilityoftheorganicnitratetoundergo
metabolic conversion to nitric oxide probably
due to a relative unavailability of reduced
intracellular thiol groups.83 Recent evidence
suggests that extracellular pathways of organic
nitrate metabolism may provide an alternative
pathway for conversion to nitric oxide.84 In the
tolerant state, there is reduced nitric oxide
generation leading to failure of smooth muscle
relaxation.
In vitro experiments have documented decreased
generation of cyclic guanosine monophosphate
inthepresenceofnitratetolerance. Thereappears
to be no abnormality of the enzyme guanylate
cyclase however which remains fully responsive
tosodiumnitroprussideandbypassesthecysteine-
dependent metabolic cascade. Several studies
have demonstrated that sulphydryl donor
administration with N-Acetylcysteine or
methioninecanreverseorpreventtolerancewhich
occurs during sustained nitrate administration.85
The value ofthis type oftreatment, inpreventing
nitrate tolerance is at present of little practical
value.
INTERVAL THERAPY FOR NITRATE
TOLERANCE
A number of investigations have demonstrated
that nitrate dosage regimens, punctuated by
prolongednitrate-free intervals, canmaintainthe
beneficial clinical effects of nitrates in angina
pectoris86' 87 and congestive cardiac failure.88 89
Overall, most studies support the view that the
use ofintermittent nitrate therapy is less likely to
result in tolerance than continuous therapy
administered by the oral,90 intravenous,85 or
transdermal9lroutes.Whilemaintainingadosage-
free interval of at least eight hours has been
successful in reducing the incidence of nitrate
tolerance, theapproach has anumberofpotential
disadvantages. The mainproblemis aworsening
ofthe chestpainduring theperiod when the drug
is withdrawn. Fortunately the adverse
consequences of intermittent therapy have been
minimal in most studies. However in a large
placebo-controlled studyintermittenttransdermal
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glyceryl trinitrate therapy produced nocturnal or
rest angina during the drug free interval in the
activetreatedgroupbutnotintheplacebogroup.92
The possibility of glyceryl trinitrate rebound
phenomenon must be kept in mind in view ofthe
previous observations experienced by munition
workers.92
Studiesofsilentmyocardialischaemiaincoronary
heartdisease have demonstrated alowfrequency
of ST segment depression in the period from
midnight to 7 am in patients with chronic stable
exertional angina. This supportstheviewthatthe
usual nitrate-free period during sleep causes
problems in patients with stable angina without
restornocturnalpain.Theuseofotherantianginal
drugs such as beta adrenoceptor antagonists and
calcium channel antagonists is clearly an
importantstrategyinprovidingprotectionagainst
ischaemia during the nitrate-free interval.
Nitrate Resistance
A variety of cardiovascular conditions are
associated with primary nitrate tolerance or
resistance. Failure to reduce blood pressure with
intravenous doses ofglyceryl trinitrate in excess
of200gg/min is commonly seen inpatients with
congestivecardiacfailure.93Possiblemechanisms
includeprimaryreceptorresistanceandsecondary
mechanisms such as catecholamine-induced
increases in vaso-constrictor tone, activation of
the renin angiotensin system, haemodilution,
impaired dilation due to vessel wall oedema and
impaired hepatic metabolism of the nitrate.94
Impaired orabsent haemodynamic responses are
alsooccasionallyobservedintheperiodfollowing
an acute myocardial function.95 Failure of the
blood vessels to dilate suggests primary receptor
tolerance which is not overcome by very high
doses.96 In a series of experiments we
demonstrated impaired vasodilator responses to
glyceryl trinitrate in patients with non-insulin
dependentdiabetes mellitus whencomparedwith
age and sex matched controls.5'6 This impaired
responsewassomewhatsurprisingsincediabetes
is associated with impaired endothelial function
andnitrate-induced vasodilation has been shown
tobeincreasedwhentheendotheliumisdamaged.
Ihavealreadydiscussedthatthebiotransformation
of organic nitrates requires intracellular
sulphydryl groups to produce vasoactive
intermediates whichstimulateguanylatecyclase.
Oxidationordepletionofthesesulphydryldonors
will lead to impaired responsiveness to organic
nitrates. In diabetes antioxidant activity is
decreased.97 98 Increased oxidative stress and
enhanced free radical activity occurring in
diabetesprobablyalterstheoxidation-reduction
equilibrium of intracellular thiols and results in
primary oxidation or depletion of the essential
sulphydryl donors. This seems the most likely
explanation forthe impaired responses observed
in diabetes.5 6 In conclusion, resistance to the
action oforganic nitrates has been demonstrated
incongestivecardiac failure, typeIIdiabetes and
following anacutemyocardialinfarction. Studies
performed in our laboratory would also suggest
that a significant percentage of normal subjects
show impaired vasodilator responses to organic
nitrates.99
CONCLUSIONS
Although nitrates have been prescribed for
patients with angina pectoris for over a century
and more recently forcongestive cardiac failure,
itis only overthe lastfew years thatnew insights
into their mode of action have been identified.
Thediscoveryoftheendogenousnitrovasodilator
nitric oxide, produced in endothelial cells by the
enzymenitricoxidesynthasehasgreatlyexpanded
our knowledge of the action of organic nitrates.
Nitricoxide,whenreleasedfromendothelialcells
can interact with vascular smooth muscle and
platelets by activating soluble guanylate cyclase
and increasing cyclic GMP. In vascular smooth
muscle this causes vasorelaxation and reduced
platelet adhesion. Exogenous nitrodilators exert
their action by producing nitric oxide. Their
vasodilator activity is greatest in blood vessels
with low basal production ofnitric oxide such as
veins and vessels in which the endothelium is
removedordamaged. Asignificantpercentageof
patientswithheartfailure,diabetesandischaemic
heart disease fail to respond to nitrate therapy
however. Long term use of organic nitrates is
associated with the development of tolerance or
ofreducedtherapeuticefficacywhenadministered
in doses or formulations which maintain
therapeuticplasmalevels overatwentyfourhour
period. The administration of N-acetylcysteine,
angiotensin converting enzyme inhibitors or
diuretics do not consistently prevent nitrate
tolerance. At present intermittent therapy is the
only satisfactory method to reduce nitrate
tolerance although other antianginal drugs may
be required during the nitrate-free intervals.
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